Ophirex, Inc.
Corte Madera, CA
- UEI
- W452WY5E2JQ9
- CAGE
- 7JTR0
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Other
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 5643 Paradise Dr # 2, Corte Madera, CA 94925, USA
- Website
- ophirex.com
- Founded
- 2015
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| DHA phase III small business innovation research prototype other transaction agreement for project titled, "broad… | Defense Health Agency | $29,999,425 | |
| Development of intravenous varespladib, a phospholipase A2 inhibitor, for the treatment of snakebite envenoming - 1… | FDA Office of Acquisition and Grant Services | $5,116,580 | |
| DHA PH II seql proposal H2S-0045, title: broad-spectrum snakebite antidote: metalloprotease inhibition to improve… | Defense Health Agency | $1,299,779 | |
| Follow on phase III research and development sbir for project titled, broad-spectrum snakebite antidote: oral product… | Defense Health Agency | $23,443,944 | |
| Covid-19 DHA 2018.1 sbir phase III medical r & d contract proposal titled: "targeting SPLA2 for treatment of acute… | Defense Health Agency | $9,228,796 |
About Ophirex, Inc.
Ophirex, Inc. is a for-profit small business located in Corte Madera, California, focused on developing medical treatments for snakebite envenomation. The company operates as a public benefit corporation with a mission to reduce death and disability from snakebite through innovative pharmaceutical research and development. Ophirex specializes in developing advanced pharmaceutical interventions, particularly focusing on a novel treatment called varespladib, which is designed to inhibit snake venom toxins and provide more effective treatment for snakebite victims.
The federal contract awards Ophirex has received are exclusively through the Small Business Innovation Research (SBIR) program, primarily from the Defense Health Agency (DHA) and the Department of the Army Medical Command. These contracts, totaling approximately $84.7 million, are specifically targeted at developing a broad-spectrum snakebite antidote with both oral and intravenous formulations. The contracts are structured as definitive and other transaction agreements, with total small business set-aside designations. The research focuses on developing varespladib, a phospholipase A2 inhibitor that can potentially improve recovery time and reduce complications from snakebite envenomation, with contract work performed in Corte Madera, California and completion dates ranging from December 2025 to May 2028.
Ophirex has received a federal grant from the FDA's Office of Medical Products and Tobacco to support the development of an intravenous varespladib formulation for snakebite envenoming treatment. The grant, awarded on September 15, 2023, with a completion date of August 31, 2026, supports a Phase IIB double-blind randomized controlled trial. The grant's project summary indicates the research aims to demonstrate the efficacy of varespladib in treating snakebite, with a focus on inhibiting snake venom secretory phospholipase A2 (sPLA2), which is found in approximately 95% of medically important venomous snakes. The research seeks to address the limitations of current antivenom treatments by developing a more comprehensive and effective intervention for snakebite victims.
Quick answers
What is Ophirex, Inc.'s UEI?
Ophirex, Inc.'s Unique Entity ID (UEI) in SAM.gov is W452WY5E2JQ9.
What is Ophirex, Inc.'s CAGE code?
Ophirex, Inc.'s CAGE code is 7JTR0.
What is Ophirex, Inc.'s primary NAICS code?
Ophirex, Inc.'s primary NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)).
Where is Ophirex, Inc. located?
Ophirex, Inc.'s physical address in SAM.gov is 5643 Paradise Dr # 2, Corte Madera, CA 94925, USA.
Is Ophirex, Inc. registered in SAM.gov?
Yes. Ophirex, Inc.'s SAM.gov registration is active through January 22, 2027.
What is Ophirex, Inc.'s most recent federal award?
Ophirex, Inc.'s most recent federal contract award is DHA phase III small business innovation research prototype other transaction agreement for project titled, "broad… (HT94252590011), from Defense Health Agency, on May 5, 2025.
On GovTribe
See Ophirex, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors